Related Experiment Video

Updated: May 19, 2026

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models

Thomas Kramer1, Fabio Lo Monte, Stefan Göring

  • 1Clemens Schöpf - Institute of Organic Chemistry and Biochemistry, Technische Universität Darmstadt , 64287 Darmstadt, Germany.

ACS Chemical Neuroscience
|August 4, 2012
PubMed

Insights

Leucine-rich repeat kinase 2 (LRRK2) mutations are linked to Parkinson's disease (PD). This review summarizes LRRK2 inhibitors and their therapeutic potential for treating PD.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Parkinson's disease (PD) is the second leading neurodegenerative disorder.
  • Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with both familial and sporadic PD.
  • LRRK2 is a key protein implicated in PD pathogenesis, making it a significant therapeutic target.

Purpose of the Study:

  • To review and summarize existing LRRK2 inhibitors.
  • To discuss the therapeutic potential of LRRK2 inhibitors for Parkinson's disease treatment.
  • To present recent in vitro and in vivo findings on LRRK2 inhibitors.

Main Methods:

  • Literature review of LRRK2 inhibitors.
  • Analysis of in vitro and in vivo study results.
  • Summary of current research on LRRK2-targeted therapies.

Main Results:

  • Several LRRK2 inhibitors have been developed.
  • The G2019S mutation is the most prevalent LRRK2 mutation in PD patients.
  • In vitro and in vivo studies show promising results for LRRK2 inhibitors.

Conclusions:

  • LRRK2 is a validated therapeutic target for Parkinson's disease.
  • Ongoing research into LRRK2 inhibitors holds promise for novel PD treatments.
  • Further investigation into LRRK2 inhibitor efficacy and safety is warranted.
Keywords:
LRRK2 inhibitorsParkinson's diseaseanimal modelsleucine-rich repeat kinase 2 (LRRK2)mutations

More Related Videos

Assaying the Kinase Activity of LRRK2 in vitro06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...